Back

Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipids as cardiovascular risk factors and treatment options Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Johannes Wikstrom

(Sweden)

4 More presentations in this session

Presentation thumbnail
Intraindividual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate-risk
Doctor T. Harb (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, asymptomatic adults
Associate Professor S. Goonewardena (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels
Doctor G. Ruotolo (Indianapolis, US)
Abstract Slides Video
Presentation thumbnail
Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes
Doctor J. Barrett (Helsinki, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids as cardiovascular risk factors and treatment options
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention
thumbnail
Congress Presentation
What’s new in LDL lowering?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources